Tumori · 2008
Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pedersini Rebecca, Vattemi Emanuela, Lusso Maria Rita, Mazzoleni Guido, Ebner Heinrich, Graiff Claudio
Аннотация
AIMS AND BACKGROUND: Advanced chemorefractory epithelial thymic tumors are still a challenge in clinical oncology. A therapeutic approach targeting a key molecular pathway could be the ideal solution in a neoplasm that can overexpress epidermal growth factor receptor (EGFR) in the epithelial component.
METHODS: A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor.
RESULTS: Strong EGFR expression was revealed by immunohistochemistry. The patient received erlotinib therapy but had obtained no response after four months of treatment.
CONCLUSION: This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.
METHODS: A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor.
RESULTS: Strong EGFR expression was revealed by immunohistochemistry. The patient received erlotinib therapy but had obtained no response after four months of treatment.
CONCLUSION: This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.